Recent Updates
Recently added Catalysts
RLAY Positive Sentiment

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Tuesday, January 3, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 4
Price reaction · baseline $14.94 (2022-12-30 close) · hit after-hours · clean, no other RLAY news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Relay Therapeutics will present at a significant healthcare conference.
  • Participation in the event highlights the company's ongoing initiatives.
  • The conference will provide a platform for networking and visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+284%
120-day peak, hindsight
Typical move
11.8%
average across 6 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
RLY-8161
Phase 1 · Advanced NRAS-Mutant Melanoma

Full Press Release Details

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 2:15 p.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation.
About Relay Therapeutics

Frequently Asked Questions

What is Relay Therapeutics?

Relay Therapeutics is a biopharmaceutical company focused on developing therapies.

Who can be contacted for information about Relay Therapeutics?

Caroline Glen can be contacted at 617-370-8837 for inquiries.

Who is the media contact for Relay Therapeutics?

Dan Budwick is the media contact at 1AB, reachable at 973-271-6085.

ShareAdd on Google
Tags: RLAY Viatris Investor Conferences Healthcare Relay Therapeutics biopharma healthcare conference J.P. Morgan
Last updated: Jan 3, 2023

Biotech snapshot

Cash runway
$911M liquidity · $18M/mo burn
~50 mo
Minimal dilution risk
Lead asset
RLY-8161Phase 1
Advanced NRAS-Mutant Melanoma →

Catalyst track record

+284%
best trade around RLAY's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RLAY.

See every catalyst's timing & PoA →